 Development potential use antibody lipopolysaccharide treatment gram-negative bacterial sepsis Gram-negative bacterial sepsis major cause lethality hospitalized patients routine therapy consisting antimicrobial agents hemodynamic monitoring fluid resuscitation metabolic support large body evidence concept Gram-negative bacterial lipopolysaccharide endotoxin LPS responsible many direct host mediator-induced deleterious effects recent work development use anti-LPS antibody preparations order lethality polyclonal monoclonal antibody preparations common deep core/lipid region LPS cross-reactive vitro cross-protective vivo wide range challenge organisms LPS preliminary clinical trials reduction lethality possible precise endotoxin epitope antibody order protection modality standard form adjunctive therapy next several years treatment Gram-negative bacterial sepsis